Relationships & Accomplishments

– Top-Line Phase 3 Data Demonstrate 86.0% Efficacy, which Met Primary Study Endpoint, and 98.7% Efficacy when Used as Directed – – Q2 2019 New Drug Application (NDA) Resubmission Planned – – Management to Host Conference Call at 8:30 a.m.… » Read More

Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019   -- 27% of subjects achieved 75% reduction… » Read More

RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection   • The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high… » Read More

RE: CANVAS Program main results We were excited to report the CANVAS Program main results at the recent meeting of the American Diabetes Association in San Diego, and to simultaneously publish the findings in the New England Journal of Medicine.… » Read More

Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack Basel, June 22, 2017 –Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of… » Read More

WALTHAM, Mass., May 2, 2017 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced positive top-line results from a Phase 3 randomized, double-blind, non-inferiority clinical trial evaluating Feraheme® (ferumoxytol) compared to Injectafer® (ferric carboxymaltose injection) in approximately 2,000 adults with iron deficiency… » Read More

Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis -48 Week Results Demonstrate Strong Clinical Benefit and Very Favorable Safety Profile- RESEARCH TRIANGLE PARK, N.C., January 6, 2017, – Viamet Pharmaceuticals, Inc. today… » Read More